<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16457150</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>02</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>12</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0300-8916</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>91</Volume>
<Issue>6</Issue>
<PubDate>
<MedlineDate>2005 Nov-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Tumori</Title>
<ISOAbbreviation>Tumori</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.</ArticleTitle>
<Pagination>
<MedlinePgn>505-12</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the clinical features of breast cancer patients with genetic susceptibility to this disease and to investigate the contribution of BRCA1 germline mutations to the phenotype of these tumors.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We reviewed the clinical and pathological records of 102 women with suspected inherited susceptibility to breast cancer consecutively seen at the Genetic Oncology Service of Parma, Italy. Sixty-two patients with a high probability of harboring a germline, cancer-predisposing mutation were tested for BRCA1 mutations. Exon 11 was screened using the protein truncation test and detected mutations were confirmed by direct sequencing (DS). All other exons were analyzed by DS.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 62 patients with a completed mutation analysis, 48 (77.4%) had wild-type BRCA1, six (9.6%) had variants of unclear significance, eight (13%) had deleterious mutations. BRCA1-associated breast cancers (BABC) were significantly less likely to be diagnosed at stage I than breast cancers in women without mutations (12.5% vs 51%; P = 0.045), more likely to have a high proliferation rate (100% vs 24%, P &lt; 0.001), and more likely to be histological grade 3 (100% vs 14%, P &lt; 0.001), estrogen and progesterone receptor negative (87.5% vs 13%, P &lt; 0.001; 75% vs 23%, P = 0.004), and p53 positive (87.5% vs 30%, P = 0.023). All tumors with BRCA1 mutations were HER-2/neu negative compared with 57% of the non-BRCA1 tumors (P = 0.04). There were no significant differences between BABC and non-BABC in 20-year relapse-free survival, 20-year event-free survival, and 20-year overall survival.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this population-based study, BABC seems to present with adverse molecular features when compared with non-BABC, although the prognosis appears to be similar.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Musolino</LastName>
<ForeName>Antonino</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy. antoninomusolino@hotmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Michiara</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bella</LastName>
<ForeName>Maria A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Naldi</LastName>
<ForeName>Nadia</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zanelli</LastName>
<ForeName>Paola</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bortesi</LastName>
<ForeName>Beatrice</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Capelletti</LastName>
<ForeName>Marzia</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soldani</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Camisa</LastName>
<ForeName>Roberta</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martella</LastName>
<ForeName>Eugenia</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Franciosi</LastName>
<ForeName>Vittorio</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Savi</LastName>
<ForeName>Mario</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neri</LastName>
<ForeName>Tauro M</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ardizzoni</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cascinu</LastName>
<ForeName>Stefano</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Tumori</MedlineTA>
<NlmUniqueID>0111356</NlmUniqueID>
<ISSNLinking>0300-8916</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019398">Genes, BRCA1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005817">Genetic Counseling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018095">Germ-Line Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006579">Heterozygote</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007558">Italy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011960">Receptors, Estrogen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011980">Receptors, Progesterone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16457150</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>